Newsweek on Sept. 21 cited Ukrainian military statements saying Ukraine airdropped suicide ground robots into Russian rear areas in northern Donetsk. Ukraine’s Third Corps said on Telegram on Sept. 20 it executed a flanking maneuver and carried out what it called the world’s first ground-robot deployment, claiming the robots — flown by heavy strike UAVs more than 10 km into enemy rear — “blinded” Russian drones via air-defence and electronic-warfare measures. Third Corps commander Brig. Gen. And

Tencent said it has partnered with Leapmotor to deploy its all-scenario AI desktop WorkBuddy. WorkBuddy supports local file handling, multi-task and multi-agent parallel operation, and a Skills and MCP ecosystem; it has been rolled out across Leapmotor’s vehicle development, intelligent driving, connected car, procurement and supply‑chain, and audit functions.

Novo Nordisk's CEO said the company must do more to rebuild investor trust as flagship drugs including Ozempic and Wegovy face patent expiries in the US and Europe over the next decade. He warned that overpromising and under-delivering quickly erodes confidence and that investors want clarity on the company's next steps. Shares fell on Monday after an investor day disappointed with limited detail on the turnaround plan. Ozempic and Wegovy account for roughly three-quarters of sales. Novo Nordisk has pledged to launch more than five major drugs by 2030 and to add over $23 bln in incremental sales by 2035; analysts say those targets largely meet expectations. BMO Capital Markets said the company remains in a proof-of-performance phase and investors need clearer visibility on next-generation drugs and likely market uptake to restore confidence.